Skip to main content

Table 1 Summary of baseline patient details

From: Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Characteristics
No. of participants 182
No. of eyes 207
Mean age (years) ± SD 80 ± 7.7
Female (%) 71
Phakic eyes (%) 78
Mean BCVA (letters) ± SD 29 ±13.2
Mean central retinal thickness (μm) ± SD 342 ± 100
Mean duration of nvAMD at switch (weeks) ± SD 129 ± 86
Mean number of ranibizumab injections at switch ± SD 12 ± 7